These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20496209)

  • 1. Residuals and outliers in replicate design crossover studies.
    Schall R; Endrenyi L; Ring A
    J Biopharm Stat; 2010 Jul; 20(4):835-49. PubMed ID: 20496209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new approach for outliers in a bioavailability/bioequivalence study.
    Liao JJ
    J Biopharm Stat; 2007; 17(3):393-405. PubMed ID: 17479389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining outlying subjects and outlying records in bioequivalence trials.
    Wang W; Chow SC
    J Biopharm Stat; 2003 Feb; 13(1):43-56. PubMed ID: 12635902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach.
    Idkaidek NM; Al-Ghazawi A; Najib NM
    Biopharm Drug Dispos; 2004 Dec; 25(9):367-72. PubMed ID: 15495146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence review for drug interchangeability.
    Chow SC; Shao J
    J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
    Panhard X; Mentré F
    Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of baseline covariates in crossover studies.
    Kenward MG; Roger JH
    Biostatistics; 2010 Jan; 11(1):1-17. PubMed ID: 19915170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.
    Chen ML; Lee SC; Ng MJ; Schuirmann DJ; Lesko LJ; Williams RL
    Clin Pharmacol Ther; 2000 Nov; 68(5):510-21. PubMed ID: 11103754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs.
    Chen YI; Huang CS
    Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
    Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
    Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new outlier identification test for method comparison studies based on robust regression.
    Rauch G; Geistanger A; Timm J
    J Biopharm Stat; 2011 Jan; 21(1):151-69. PubMed ID: 21191861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new strategy of outlier detection for QSAR/QSPR.
    Cao DS; Liang YZ; Xu QS; Li HD; Chen X
    J Comput Chem; 2010 Feb; 31(3):592-602. PubMed ID: 19530115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.